IL6 and Sepsis: The IL‐6 inhibitor tocliziumab has been used successfully in cytokine release syndrome following chimeric antigen receptor T‐cell therapy (CAR‐T) [11], and IL‐1 blockade with anakinra has proven beneficial in patients with a hyperinflammatory state secondary to sepsis [12].